Dofetilide for atrial fibrillation
Article Abstract:
Pfizer has developed an anti-arrhythmic drug called dofetilide for the treatment of atrial fibrillation and atrial flutter. These are two types of arrhythmias that affect the upper chamber of the heart. Sold under the trade name Tikosyn, the drug blocks a specific potassium channel. It is about as effective as the anti-arrhythmic drug sotalol, but one of its side effects is a serious arrhythmia called torsades des pointes. For this reason, all patients who receive it should be on a heart monitor.
Publisher: Medical Letter, Inc.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 2000
Evaluation, Product/Service Evaluation, Drug therapy, Atrial fibrillation, Atrial flutter, Tikosyn (Medication)
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
A promoter polymorphism of the insulin-like growth factor-I gene is associated with left ventricular hypertrophy
Article Abstract:
mex
Publisher: British Medical Association
Publication Name: Heart
Subject: Health
ISSN: 1355-6037
Year: 2005
Netherlands, Science & research, Research, Medical examination, Genetic aspects, Genetic polymorphisms, Insulin-like growth factor 1, Insulin-like growth factor I, Heart enlargement, Heart hypertrophy
Publication Name: Heart
Subject: Health
ISSN: 1355-6037
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Similar abstracts:
- Abstracts: Trichomonas vaginalis: signs, tests and treatment. Statistical tests: Continuous data. Too hot to handle: ministers have been somewhat inept at handling the fiascos over HIV tests, the Pill and BSE
- Abstracts: Talking trash: the economic and environmental issues of landfills. Environmental impacts of Hurricane Mitch
- Abstracts: Dalteparin - another low-molecular-weight heparin. Improvement in heparin prophylaxis. Heparin cofactor II-proteinase reaction products exhibit neutrophil chemoattractant activity
- Abstracts: The drug crisis: hearing and heeding its message. Removing the glamour. Empowering the impaired: A parents' guide to technological advancements for the hearing and visually impaired
- Abstracts: Intracranial pressure monitoring: review of risk factors associated with infection. part 2 Vital signs: are we monitoring the right parameters?
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.